Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF)

Journal of Pharmaceutical Sciences

Volumn 92, Issue 10, 2003, Pages 2117-2127

  Luo, Yongde ^a   Cho, Hyun Hee ^a   McKeehan, Wallace L ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Affinity; Anticoagulant; Binding; Biotechnology; Drug design; Fibroblast growth factor 7 (FGF7); Heparin; Neutralization; Protein; Separation science; Structure activity relationship

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; HEPARIN; POLYPEPTIDE; PROTAMINE SULFATE; PROTHROMBIN ANTIBODY;

ARTICLE; BLOOD CLOTTING; DRUG DESIGN; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG PURIFICATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0141619276     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10472     Document Type: Article

References (51)

1. Roden L. 1989. Highlights in the history of heparin. In: Lane DA, Lindahl U, editors. Heparin. London: Edward Arnold. pp 1-19.
2. Lindahl U, Kusche-Gullberg M, Kjellen L. 1998. Regulated diversity of heparan sulfate. J Biol Chem 273:24979-24982.
3. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. 1983. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116:492-499.
4. Conrad EH. 1998. Antithrombin, the prototypic heparin-binding protein. In: Conrad EH, editor. Heparin-binding protein. San Diego, CA: Academic Press, pp 203-231.
5. Loganathan D, Wang HM, Mallis LM, Linhardt RJ. 1990. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362-4368.
6. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. 1992. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267: 12528-12538.
7. Olson ST, Bjork I. 1994. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 20:373-409.
8. Rezaie AR. 2000. Heparin-binding exosite of factor Xa. Trends Cardiovasc Med 10:333-338.
9. Barrowcliffe TW, Johnson EA, Thomas DP. 1992. Biochemistry of anticoagulant action in vitro. In: Barrowcliffe TW, Johnson EA, Thomas DP, editors. Low molecular weight heparin. New York: John Wiley & Sons Ltd., pp 17-38.
10. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. 1997. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 100:67-75.
11. Ahmed T, Ungo J, Zhou M, Campo C. 2000. Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides. J Appl Physiol 88:1721-1729.
12. Folkman J, Shing Y. 1992. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 13:355-364.
13. Lane DA, Adams L. 1993. Non-anticoagulant uses of heparin. N Engl J Med 329:129-130.
14. Sache E, Maillard M, Malazzi P, Bertrand H. 1989. Partially N-desulfated heparin as a non-anticoagulant heparin: Some physico-chemical and biological properties. Thromb Res 55:247-258.
15. Sarret M, Kher A, Toulemonde F. 1999. Marketed low molecular weight heparins. In: Sarret M, Kher A, Toulemonde F, editors. Low molecular weight heparin therapy. New York: Marcel Dekker, pp 1-10.
16. Yu G, LeBrun L, Gunay NS, Hoppensteadt D, Walenge JM. 2000. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb Res 100:549-556.
17. Shriver Z, Sundaram M, Venkataraman G; Fareed J, Linhardt R, Biemann K, Sasisekharan R. 2000. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 97:10365-10370.
18. Fryer A, Huang YC, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J. 1997. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 282: 208-219.
19. Kouretas PC, Hannan RL, Kapur NK, Hendrickson R, Redmond EM, Myers AK, Kim YD, Cahill PA, Sitzmann JR. 1998. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: Role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol 30:2669-2682.
20. Mochizuki S, Hamato N, Hirose M, Miyano K, Ohtami W, Kameyama S, Kuwae S, Tokuyama T, Ohi H. 2001. Expression and characterization of recombinant human antithrombin III in Pichia pastoris. Protein Expr Purif 23:55-65.
21. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES. 1998. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 91:4561-4571.
22. Guimond SE, Turnbull JE. 1999. Fibroblast growth factor receptor signaling is dictated by specific heparan sulphate saccharides. Curr Biol 9:1343-1346.
23. McKeehan WL, Wang F, Kan M. 1998. The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 59:135-176.
24. Klint P, Claesson-Welsh L. 1999. Signal transduction by fibroblast growth factor receptors. Front Biosci 4:D165-D177.
25. Fernig DG, Gallagher JT. 1994. Fibroblast growth factors and their receptors: An information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 5:353-377.
26. Ornitz DM. 2000. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22:108-112.
27. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2: Reviews 3005.
28. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. 1993. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259:1918-1921.
29. Kan M, Wu X, Wang F, McKeehan WL. 1999. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 274:15947-15952.
30. Faham S, Linhardt RJ, Rees DC. 1998. Diversity does make a difference: Fibroblast growth factor-heparin interactions. Curr Opin Struct Biol 8: 578-586.
31. Ye S, Luo Y, Lu W, Jones RB, Linhardt RJ, Capila I, Toida T, Kan M, Pelletier H, McKeehan WL. 2001. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry 40:14429-14439.
32. Plotnikov AN, Eliseenkova AV, Ibrahimi OA, Shriver Z, Sasisekharan R, Lemmon MA, Mohammadi M. 2001. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. J Biol Chem 276:4322-4329.
33. Hecht HJ, Adar R, Hofmann B, Bogin O, Weich H, Yayon A. 2001. Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces. Acta Crystallogr D Biol Crystallogr 57:378-384.
34. Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova V, Basilico C, Mohammadi M. 2001. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Mol Cell Biol 21:5946-5957.
35. DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA. 1998. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393: 812-817.
36. Pye DA, Vives RR, Hyde P, Gallagher JT. 2000. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: Differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 10:1183-1192.
37. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. 1996. Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120.
38. Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL. 1998. The glycine box: A determinant of specificity for fibroblast growth factor. Biochemistry 37:16506-16515.
39. Lu W, Luo Y, Kan M, McKeehan WL. 1999. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274:12827-12834.
40. Jang JH, Wang F, Kan M. 1997. Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2IIIb with stromal-derived fibroblast growth factor-7. In Vitro Cell Dev Biol Anim 33:819-824.
41. Hsu Y, Hsu EW, Katta V, Brankow D, Tseng J, Hu S, Morris CF, Kenney WC, Lu HS. 1998. Human keratinocyte growth factor recombinantly expressed in Chinese hamster ovary cells: Isolation of isoforms and characterization of post-translational modifications. Protein Expr Purif 12:189-200.
42. Nybo RE, Everton EN, Morris CF. 1997. Mitogenic activity of keratinocyte growth factor amino-terminal truncation mutants: Deletion of amino acid residues 1-15 through 1-27. In Vitro Cell Dev Biol Anim 33:606-607.
43. Burnouf T, Radosevich M. 2001. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods 49:575-586.
44. Osslund TD, Syed R, Singer E, Hsu EW, Nybo R, Chen BL, Havey T, Arakawa T, Narhi LO, Chirino A, Morris CF. 1998. Correlation between the 1.6 Å crystal structure and mutational analysis of keratinocyte growth factor. Protein Sci 7:1681-1690.
45. Williams EC, Huppert BJ, Asakura S. 1992. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: Comparison with other plasma and platelet proteins. J Lab Clin Med 20:159-167.
46. Shanberge JN, Quattrociocchi-Longe TM, Martens MH. 1987. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. Thromb Res 46:89-100.
47. Poon MC, Hurst RE, Rives MS. 1982. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density. Thromb Haemost 47:162-165.
48. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. 1986. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 261:3980-3986.
49. Swartz JR. 2001. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 12:195-201.
50. Petsch D, Anspach FB. 2000. Endotoxin removal from protein solutions. J Biotechnol 76:97-119.
51. Sharma SK. 1986. Endotoxin detection and elimination in biotechnology. Biotechnol Appl Biochem 8:5-22.